Who owns Viridian Therapeutics, Inc.\DE (MGEN)? Elite investor 13F holders
3 tracked elite investors reported holding Viridian Therapeutics, Inc.\DE as of 2026-06-30, including Caligan Partners, D.E. Shaw, Renaissance Technologies LLC. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
3 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Caligan Partners | VIRIDIAN THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 40303431.00 USD | 2193981.000000 | Shares | buy | Original filing |
| D.E. Shaw | VIRIDIAN THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 21717418.00 USD | 1182222.000000 | Shares | reduce | Original filing |
| Renaissance Technologies LLC | VIRIDIAN THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 14119182.00 USD | 768600.000000 | Shares | add | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.